VJHemOnc is committed to improving our service to you

EBMT 2020 | LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT

VJHemOnc is committed to improving our service to you

Christian Gisselbrecht

Christian Gisselbrecht, MD, Saint Louis Hospital, Paris, France, discusses long-term survival after 2 year’s event-free survival in relapsed diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplantation (ASCT) in the two randomized trials LY.12 (NCT00078949) and CORAL (NCT00137995). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter